Eptifibatide Powder: A Potent Platelet Aggregation Blocker for Acute Coronary Syndrome and PCI
Revolutionizing cardiovascular interventions with advanced antithrombotic peptide solutions.
Get a Quote & SampleProduct Core Value
Eptifibatide Powder
Eptifibatide Powder is a cyclic heptapeptide that functions as a selective platelet glycoprotein IIb/IIIa receptor antagonist, significantly inhibiting thrombus formation by preventing fibrinogen from binding to platelets. Its rapid onset and short half-life make it an ideal agent for precise anticoagulant management during critical cardiovascular procedures.
- Experience rapid onset of action and a short half-life, crucial for precise anticoagulant control when using this platelet aggregation blocker for ACS.
- Prevent perioperative thrombotic complications effectively with this key antithrombotic agent for PCI.
- Benefit from targeted antithrombotic therapy during interventional treatments, leveraging the properties of this Eptifibatide powder raw material.
- Ensure high purity (>99%) and white powder appearance for optimal use in critical medical applications requiring a potent platelet glycoprotein IIb/IIIa receptor antagonist.
Product Advantages
Rapid and Controlled Action
Achieve immediate therapeutic effects and maintain precise anticoagulant levels, vital when seeking a platelet aggregation blocker for ACS.
Enhanced Safety in Procedures
Minimize risks associated with thrombotic events during interventional cardiology, a key benefit of this PCI thrombotic complications prevention solution.
Therapeutic Versatility
Effectively manage conditions like acute coronary syndrome and high-risk unstable angina pectoris with this essential antithrombotic therapy during interventional treatment agent.
Key Applications
Acute Coronary Syndrome Management
Provides crucial antithrombotic support for patients with non-ST segment elevation ACS, a primary use case for Eptifibatide powder raw material.
Percutaneous Coronary Intervention (PCI)
Aids in the prevention of thrombotic complications during PCI procedures, highlighting its role in PCI thrombotic complications prevention.
Unstable Angina Therapy
Offers effective treatment for high-risk unstable angina pectoris, showcasing its utility in high-risk unstable angina pectoris therapy.
Cardiogenic Shock Intervention
Supports coronary intervention in patients with cardiogenic shock, demonstrating its application in cardiogenic shock coronary intervention.